Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association

(2017) Daniel E. Freedberg et al.   GASTROENTEROLOGY

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Diagnosis and Management of Functional Heartburn

(2016) Christine Hachem et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Sustained Acid Suppression by Potassium-Competitive Acid Blocker (P-CAB) May Be An Attractive Treatment Candidate for Patients with Eosinophilic Esophagitis

(2016) Norihisa Ishimura et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

(2016) Helen Jenkins et al.   CLINICAL DRUG INVESTIGATION

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

(2016) Yoshikazu Kinoshita et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa

(2016) Jun Matsukawa et al.   DIGESTIVE DISEASES AND SCIENCES

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Influence of potassium-competitive acid blocker on the gut microbiome ofHelicobacter pylori-negative healthy individuals

(2016) Taketo Otsuka et al.   GUT

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus

(2016) Kwong Ming Fock et al.   GUT

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Solitary Gastric Carcinoid Tumor Associated with Long-Term Use of Omeprazole: A Case Report and Review of the Literature

(2015) Nina Nandy et al.   DIGESTIVE DISEASES AND SCIENCES

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

(2013) John Dent et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Acid Pocket: A Target for Treatment in Reflux Disease?

(2013) Peter J Kahrilas et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

An Alginate-Antacid Formulation Localizes to the Acid Pocket to Reduce Acid Reflux in Patients With Gastroesophageal Reflux Disease

(2013) Wout O. Rohof et al.   Clinical Gastroenterology and Hepatology

Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review

(2013) Hashem B El-Serag et al.   GUT

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors

(2013) Jai Moo Shin et al.   Journal of Neurogastroenterology and Motility

Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors

(2012) Daniel Sifrim et al.   GUT

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

Systematic review of the epidemiology of gastroesophageal reflux disease in Japan

(2011) Yoshikazu Kinoshita et al.   JOURNAL OF GASTROENTEROLOGY

The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects

(2010) R. H. HUNT et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Matched Case-Control Study of a Novel Acid-Pump Antagonist and Proton-Pump Inhibitor for the Treatment of Iatrogenic Ulcers Caused by Endoscopic Submucosal Dissection

(2010) Yong Gil Kim et al.   Gut and Liver

Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

(2010) Hyung-Keun Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies

(2009) P. SHARMA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy

(2009) D. C. METZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment?

(2009) Peter Bytzer   Clinical Gastroenterology and Hepatology

Is Conventional Endoscopic Identification of Non-Erosive Reflux Disease Adequate?

(2008) Gary W. Falk   DIGESTION

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY